Anthony M. Manning
CIK: 0001716468
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Palatin Reports Q4 2026 Results With Lower Losses. Palatin Technologies released its fiscal year 2026 financial results, reporting a Q4 loss of $1.11 per share, an improvement from the $2.73 loss in the same period last year. The company also reported sales of $300,770 for the quarter. This update provides the latest financial snapshot for the stock, which is currently trading near its 52-week low.
Transaction History
| GLUE | ▲ Buy | Option Exercise | 10,000 | $42K | 6/29/2026 | View on chart |
| GLUE | ▼ Sell | Open Market | 10,000 | $231K | 6/29/2026 | View on chart |
| GLUE | ▲ Buy | Option Exercise | 10,000 | $42K | 5/21/2026 | View on chart |
| GLUE | ▼ Sell | Open Market | 10,000 | $180K | 5/21/2026 | View on chart |
| PTN | ▲ Buy | Grant | 12,000 | $0 | 7/15/2024 | View on chart |
| PTN | ▲ Buy | Grant | 10,000 | $0 | 6/20/2023 | View on chart |
| PTN | ▲ Buy | Grant | 73,000 | $0 | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Monte Rosa draws analyst attention on pipeline review and routine disclosures
Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.
Monte Rosa draws analyst attention on pipeline review and routine disclosures. Recent coverage for Monte Rosa Therapeutics has focused on the company's drug pipeline and balance sheet position, alongside standard disclosures. The company reported inducement grants to employees under a Nasdaq listing rule, which is a routine corporate event. Separately, Monte Rosa announced participation in upcoming investor conferences, giving management a venue to update the market on its clinical programs. Together, these items keep the company visible to investors without altering its underlying outlook.